Vupputuri Suma, Fox Caroline S, Coresh Josef, Woodward Mark, Muntner Paul
Center for Health Research, Kaiser Permanente Georgia, Atlanta, GA 30305, USA.
Am J Kidney Dis. 2009 Jun;53(6):993-1001. doi: 10.1053/j.ajkd.2008.12.043. Epub 2009 Apr 25.
Adiposity is associated with cystatin C. Cystatin C-based glomerular filtration rate (GFR) equations may result in overestimation of chronic kidney disease (CKD) prevalence at greater body mass index (BMI) levels.
Cross-sectional.
SETTING & PARTICIPANTS: 6,709 US adult Third National Health and Nutrition Examination Survey participants.
BMI.
Absolute percentage of difference in prevalence of stage 3 or 4 CKD between creatinine- and cystatin C-based estimating equations by level of BMI.
Normal weight, overweight, and obesity were defined as BMI of 18.5 to less than 25.0, 25 to less than 30.0, and 30 kg/m(2) or greater, respectively. Stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR], 15 to 59 mL/min/1.73 m(2)) was defined using the 4-variable creatinine-based Modification of Diet in Renal Disease Study equation (eGFR(MDRD)); cystatin C level, age, sex, and race equation (eGFR(CysC,age,sex,race)); cystatin C-only equation (eGFR(CysC)); cystatin C level of 1.12 mg/L or greater (increased cystatin C); and an equation incorporating serum creatinine level, cystatin C level, age, sex, and race (eGFR(Cr,CysC,age,sex,race)).
Differences in stage 3 or 4 CKD prevalence estimates between eGFR(CysC,age,sex,race), eGFR(CysC), and increased cystatin C, separately, and eGFR(MDRD) were greater at higher BMI levels. Specifically, compared with estimates derived using eGFR(MDRD) for normal-weight, overweight, and obese participants, estimated prevalences of stage 3 or 4 CKD were 2.1%, 3.0%, and 6.5% greater when estimated by using eGFR(CysC,age,sex,race) (P trend = 0.005); 0.1%, 0.6%, and 2.2% greater for eGFR(CysC) (P trend = 0.03); 2.9%, 5.2%, and 9.5% greater for increased cystatin C (P trend < 0.001); and -0.1%, -0.4%, and 0.0% greater for eGFR(Cr,CysC,age,sex,race), respectively (P trend = 0.7).
No gold-standard measure of GFR was available.
BMI may influence the estimated prevalence of stage 3 or 4 CKD when cystatin C-based equations are used.
肥胖与胱抑素C相关。基于胱抑素C的肾小球滤过率(GFR)方程可能会导致在更高体重指数(BMI)水平下高估慢性肾脏病(CKD)的患病率。
横断面研究。
6709名美国成年第三次全国健康和营养检查调查参与者。
BMI。
根据BMI水平,基于肌酐和基于胱抑素C的估算方程之间3期或4期CKD患病率的绝对差异百分比。
正常体重、超重和肥胖分别定义为BMI为18.5至小于25.0、25至小于30.0以及30kg/m²或更高。3期或4期CKD(估算肾小球滤过率[eGFR],15至59mL/min/1.73m²)使用基于肌酐的4变量肾脏病饮食改良研究方程(eGFR[MDRD])定义;胱抑素C水平、年龄、性别和种族方程(eGFR[CysC,age,sex,race]);仅胱抑素C方程(eGFR[CysC]);胱抑素C水平为1.12mg/L或更高(胱抑素C升高);以及纳入血清肌酐水平、胱抑素C水平、年龄、性别和种族的方程(eGFR[Cr,CysC,age,sex,race])。
eGFR(CysC,age,sex,race)、eGFR(CysC)和胱抑素C升高分别与eGFR(MDRD)之间,3期或4期CKD患病率估计值的差异在较高BMI水平时更大。具体而言,与使用eGFR(MDRD)得出的正常体重、超重和肥胖参与者的估计值相比,使用eGFR(CysC,age,sex,race)估计的3期或4期CKD患病率分别高2.1%、3.0%和6.5%(P趋势 = (0.005);eGFR(CysC)分别高0.1%、0.6%和2.2%(P趋势 = 0.03);胱抑素C升高分别高2.9%、5.2%和9.5%(P趋势 < 0.001);而eGFR(Cr,CysC,age,sex,race)分别高 - 0.1%、 - 0.4%和0.0%(P趋势 = 0.7)。
没有可用的GFR金标准测量方法。
当使用基于胱抑素C的方程时,BMI可能会影响3期或4期CKD的估计患病率。